EMERYVILLE, Calif., Feb. 3, 2016 /PRNewswire/ -- Trianni, Inc. is delighted to announce that the Trianni Mouse Platform was granted an Australian Patent. The Trianni Mouse Platform provides the complete human antibody repertoire for the facile isolation of monoclonal antibodies.
“The addition of the Australian patent to our portfolio strengthens Trianni’s position in monoclonal antibody discovery platform,” commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of Trianni. “It recognizes the novelty of the approach that Trianni used to generate the platform. Rather than cloning DNA fragments from the human genome, Trianni used chemically synthesized large DNA segments with sequences that do not exist in nature. Designed in silico, these segments are modified versions of the mouse immunoglobulin loci, with human exons embedded in mouse control regions and intergenic DNA.”
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to enterprise recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Contacts
Zishan Haroon, MD, PhD
Chief Business Officer
1.415.231.0257 [o]
drz@trianni.com
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
mandy.boyd@trianni.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trianni-announces-issuance-of-patent-in-australia-300214509.html
SOURCE Trianni, Inc.
